Speakers - Symposia 2018

Benjamin Horning

Senior Scientist

Vividion

Benjamin Horning (Benji) was born in Portland, Oregon. He received his undergraduate degree in Biochemistry at the University of Oregon, working with professor Michael Haley studying metallabenzenes. He then performed graduate studies with professor David MacMillan at Princeton University, where he studied the total synthesis of the akuammiline alkaloid natural product Vincorine. His postdoctoral studies, with professor Benjamin Cravatt, focused on the development of methyltransferase photoaffinity probes. He began work at Vividion immediately following his postdoctoral studies, beginning in June of 2016. One of his many job functions at Vividion is to manage Dotmatics functionality, including user administration, form building, data analysis, project views and templates, and training.
 

Jarrod Medeiros

Director, Informatics and IT

Casma Therapeutics

I’m a typical scientist-turned-informatics person. After working in the lab at companies like Novartis, Millenium, and EMD Serono, I realized I was a data nerd and found my way to informatics software at IDBS and Riffyn. After 8 years on the vendor side, I made the jump back to biotech and have been covering all aspects of IT and Informatics for Casma since shortly after inception.
 

Robert Coner

Director, Informatics

Peloton Therapeutics

Bob is the Director of Informatics at Peloton Therapeutics which was recently purchased by Merck for up to $2.2 Billion. He is responsible for all of Peloton’s IT and Informatics infrastructure.
 

Gerhard Frey, Ph.D.

Vice President of Scientific Collaborations

BioAtla

Ph.D. at the University of Regensburg, Germany studying the molecular biology of Archaea.
Assistant Professor University of Regensburg, Institute for Microbiology. (1992-1998)
Diversa Corp., San Diego, Staff Scientist – Principal Scientist. (1998 -2007)
BioAtla, San Diego, VP Technology Development, VP R&D Collaborations. (2007-present)
Over 20 years of experience in protein and antibody engineering. In charge of in house ADC conjugation and cell line development.
 

Isabelle Okuda

Associate Director of Analytical Chemistry and Compound Management

Vividion

Isabelle Okuda, comes originally from Canada, with an Undergraduate degree from the University of Toronto, and Graduate Degree from the University of Western Ontario.
Isabelle has worked in Pharmaceuticals, Electronic Materials, Food, Academics and Biotech for over 25 years. She loves challenges and innovation and has been at Vividion, Therapeutics for over 2 years.
 

Jillian DiMuzio

Director, High-throughput Screening & Automation

Immunome

Jillian DiMuzio is the Director of High-throughput Screening and Automation at Immunome. To this role, Ms. DiMuzio brings nearly 25 years of assay development and small molecule / biologics screening expertise. Her team is responsible for interrogating Immunome’s monoclonal antibody repertoire against a vast antigen landscape as well as coordinating data analytics and interpretation. Prior to joining Immunome in 2017, Ms. DiMuzio was recruited by Idera Pharmaceuticals in Cambridge, Massachusetts to develop mid-scale in vitro / in vivo screens for antisense oligonucleotides and TLR agonists as therapeutics towards oncology and other rare disease indications. Ms. DiMuzio began her career at Merck and Co. in West Point, PA where some of her most notable scientific achievements lead to the association of Presenilin I with gamma-secretase, co-authoring several publications in peer-reviewed journals, including Nature, on the topic. Additionally, Ms. DiMuzio developed an elaborate five-panel enzyme screen which led directly to the discovery and acceptance of multiple pre-clinical candidates with two realizing commercial launch for the treatment of Hepatitis C virus. Ms. DiMuzio hails from Philadelphia and holds a Bachelor of Science degree in Biology from Chestnut Hill College. She currently resides in Harleysville, PA with her husband and son.
 

Amy E. Kallmerten

Scientific Data Stewardship, Discovery, Preclinical & Early Development IT

Merck

Dr. Kallmerten has held several roles related to the development and marketing of technical products with a heavy focus on enabling scientists and protecting the resulting intellectual property. She is has a strong desire to champion the needs of end-users and fulfill her ultimate career goal of facilitating the advancement of science through technology. Currently, in the Information Technology organization at Merck & Co, Dr. Kallmerten is the User Success and Change Enablement lead on the Research Life Science Cloud program where she is accountable for the overall success of both technical and scientific users including driving overall program strategy, training approach and execution, communication strategy, driving user adoption, and designing and tracking success metrics. Outside of Merck she’s also heavily involved with the Society for Laboratory Automation and Screening including being selected as the co-chair for the 2021 SLAS conference in San Diego.
 

Samuel G. Tanner, Jr.

Director, High-throughput Screening & Automation

Southern Research

Tanner received his master’s degree in synthetic organic chemistry from the University of Alabama at Birmingham. The focus of his graduate work was the synthesis of novel blockers of the voltage-gated sodium channels as potential therapeutics to treat breast and prostate cancers. Tanner joined Southern Research in May 2016, focusing his efforts on the synthesis of small molecule inhibitors as potential therapeutics for the treatment of influenza and HIV-1 research. Since June 2018, Tanner assumed the role of director of Compound Management for the DDS Chemistry Department.
 

Janosch Achenbach

Computational Chemist

BASF SE

Janosch is a Bioinformatician by training and joined BASF about 6 years ago. He started working in their Molecular Modelling team supporting the early fungicide research at BASF. About three years ago they established a dedicated cheminformatics team in which he is responsible for data management, machine-learning and application development for R&D.
 

Michael Beckmann

Group IT – Business Account Management

Clariant International Ltd.

Michael Beckmann works for Clariant Group IT in Switzerland. Michael has a strong chemistry background and worked for more than 15 years in analytical and R&D focused labs. For the past 20 years Michael has been working for Clariant IT in different roles and responsibilities.

In his current role as an IT Business Account Manager, Michael is managing all R&D related IT requirements. 7 years ago he identified the issues resulting from a high diverse setup of applied IT tools in R&D. As a consequence and as part of the strategic alignment between IT and the R&D units, a fully-fledged requirement analysis for an ELN was conducted in 2016, and starting 2017 Clariant is about to complete the global Dotmatics ELN implementation project by end of 2020. Michael is supporting this project and takes care that the program to modernize IT in R&D leads to seamless processes, paperless workplaces, real knowledge management and a fully connected environment that is mobile enabled in order to generate more lab bench-time.
 

Neal Dunkinson

Head of Technical Sales

SciBite

Neal plays a crucial role at SciBite, helping understand the objectives of our customers and tailoring demonstrations of our solutions to meet their needs. With an MSc in Genetic Epidemiology, Neal has been in the life sciences industry for over 15 years, gaining valuable experience building and leading teams and supporting customer relationships during various consulting, sales and analytics roles within Thomson Reuters and Dassault Systems. He’s not all work and no play, outside of the office he loves to play underwater hockey, mountain bike, snowboard or just relax playing the piano whenever he’s not being run off my feet by his children and dog.
 

Raquel Miranda Hoggett

Small Molecule Discovery Workflows Service Manager

Roche

Raquel Miranda Hoggett originally graduated as a computer engineer and has been managing scientific applications in the chemistry research area for over 10 years. Now as the service manager of the small molecules workflow at Roche pRED she is responsible for, among other things, the management of the electronic lab notebooks for the chemistry research group. Today she will be giving us some insights into our latest project which is focused on improving the capabilities of the existing ELN.
 

Steve McCoy

Business Development Manager

TetraScience

Steve has been a member of the go-to-market team at TetraScience for over three years, and has responsibility for sales, marketing, and business development relationships.
 

Hetal Patel, M.S.

Senior Scientist, Data II

AbbVie Inc.

Having been at AbbVie for almost 12 Years, Hetal is currently working as a Data Scientist. She has implemented Studies for plate-based screening and creating multiple dashboards and bioassay QC tools using Spotfire. In the past, She has spent 6 years in a high throughput screening group to design and run screens based on biochemical, Cell Based - High Content Analysis, Reporter Gene Assays, GPCR using Tetra assay for all therapeutic areas. Along with running screen she also worked on improving data analysis software with newer enhancement of the internal build software (MAPs). Hetal implemented the first Naive Biologics Library screen at AbbVie. Hetal has worked in a Dermatology group to generate data for candidate selection while bringing new technologies into the group and also worked for Abbott Vascular on Drug Eluting Stent
 

Gautam Agnihotri

Senior Director, Research Service Division

WuXi AppTec

Dr. Gautam Agnihotri has more than 18 years of experience in the pharmaceutical and biotech industry. After graduating with a Ph.D. in Biological Chemistry from the University of Minnesota, Minneapolis, he joined SmithKline Beecham (now GSK) as a post-doctoral scientist in 2000, where he worked in the area of HTS assay development for anti-infective targets. He joined NeoGenesis, Inc. in 2002 where he was part of a group that provided biochemical and cell assay support for external collaborations as well as internal discovery programs.
After NeoGenesis was acquired by Schering-Plough, he joined the HTS group of Schering-Plough in 2006, where he supervised assay development, screening, data analysis, and post-HTS followup for a wide variety of target classes from diverse disease areas in both medium throughput (96/384) and high-throughput (1536) formats.
After the acquisition of Schering-Plough by Merck, Dr. Agnihotri joined the In Vitro Pharmacology group at Merck Research Labs in Kenilworth, NJ in 2010. He led a team in the Biochemistry/Biophysics group to develop assays and determine mode of action for multiple protease targets and then moved to the Screening Operations team in 2012 where he led a team of compound management scientists, automation engineers, and biologists. He left Merck in June 2014 to join WuXi AppTec, and is currently Senior Director in the Research Service Division.
Dr. Agnihotri’s skills span the areas of biochemistry and enzymology, as well as medium and high-throughput screening, automation, data analysis and reporting. In his current role, he helped in the establishment of WuXi AppTec labs in New Jersey and is leading biochemical/biophysical assay development and optimization.
 

Michael Beluch

Lead, Digital Capability Management, Leads Discovery and Optimization

Bristol-Myers Squibb

Mike Beluch is the Lead Digital Capability Manager for the Leads Discovery & Optimization group at Bristol-Myers Squibb. Mike has worked in the chemical and pharmaceutical industries for 25 years, starting his career at the bench as a Molecular Biologist, specializing for many years in nuclear hormone receptors and cholesterol efflux pathways. In 2004, Mike transitioned to IT at BMS, advancing a 'user-perspective', while working to develop, integrate, and support applications used in Research and Discovery Biology. His responsibilities have been to support existing and emerging technologies in the High-throughput screening group via software development and third-party software integration. In 2019, Mike transitioned to a broader role as a DCM Lead for LDO, responsible for defining strategic technology road-maps and developing solution architectures for new business capabilities.
 

Johannes H. Voigt

Directory, Computational Chemistry

Foghorn Therapeutics

Johannes Voigt is Director of Computational Chemistry at Foghorn Therapeutics, where he is responsible for ligand and structure based drug design, chemoinformatics, and decision enabling tools. Prior to joining Foghorn, Dr. Voigt contributed to drug discovery projects at Schering-Plough/Merck, Gilead, and CHDI. He is co-author of over 50 publications.
 

Hetal Patel, M.S.

Senior Scientist, Data II

AbbVie Inc.

Having been at AbbVie for almost 12 Years, Hetal is currently working as a Data Scientist. She has implemented Studies for plate-based screening and creating multiple dashboards and bioassay QC tools using Spotfire. In the past, She has spent 6 years in a high throughput screening group to design and run screens based on biochemical, Cell Based - High Content Analysis, Reporter Gene Assays, GPCR using Tetra assay for all therapeutic areas. Along with running screen she also worked on improving data analysis software with newer enhancement of the internal build software (MAPs). Hetal implemented the first Naive Biologics Library screen at AbbVie. Hetal has worked in a Dermatology group to generate data for candidate selection while bringing new technologies into the group and also worked for Abbott Vascular on Drug Eluting Stent
 

Gautam Agnihotri

Senior Director, Research Service Division

WuXi AppTec

Dr. Gautam Agnihotri has more than 18 years of experience in the pharmaceutical and biotech industry. After graduating with a Ph.D. in Biological Chemistry from the University of Minnesota, Minneapolis, he joined SmithKline Beecham (now GSK) as a post-doctoral scientist in 2000, where he worked in the area of HTS assay development for anti-infective targets. He joined NeoGenesis, Inc. in 2002 where he was part of a group that provided biochemical and cell assay support for external collaborations as well as internal discovery programs.
After NeoGenesis was acquired by Schering-Plough, he joined the HTS group of Schering-Plough in 2006, where he supervised assay development, screening, data analysis, and post-HTS followup for a wide variety of target classes from diverse disease areas in both medium throughput (96/384) and high-throughput (1536) formats.
After the acquisition of Schering-Plough by Merck, Dr. Agnihotri joined the In Vitro Pharmacology group at Merck Research Labs in Kenilworth, NJ in 2010. He led a team in the Biochemistry/Biophysics group to develop assays and determine mode of action for multiple protease targets and then moved to the Screening Operations team in 2012 where he led a team of compound management scientists, automation engineers, and biologists. He left Merck in June 2014 to join WuXi AppTec, and is currently Senior Director in the Research Service Division.
Dr. Agnihotri’s skills span the areas of biochemistry and enzymology, as well as medium and high-throughput screening, automation, data analysis and reporting. In his current role, he helped in the establishment of WuXi AppTec labs in New Jersey and is leading biochemical/biophysical assay development and optimization.
 

JW Feng, PhD

Director of Discovery Data Science

Denali Therapeutics Inc.

JW is passionate about applying computer science to solve problems in drug discovery. He has been leveraging expertise in software development and molecular modeling to invent new drugs to treat unmet medical needs. His passion for informatics empowers drug discovery scientists by removing both technical and behavioral barriers to organizing, sharing and analyzing data. In the last four years, JW built Denali’s molecular modeling and informatics group to support both small molecule and biotherapeutics discovery. Key contributions from his team lead to inventions of multiple drugs entering clinical trials. Prior to Denali, JW was a Scientist at Genentech supporting small molecule drug discovery. JW received bachelor of science degrees in Computer Science and Biochemistry at The Ohio State University. After college, he was seduced by the Y2K rage and joined IBM as a software engineer only to realize his true love was to apply computer science to solve problems in biology. He found that at Washington University in St. Louis where he developed a systematic ligand docking algorithm that decouples sampling and scoring. He also experimentally tested hypotheses generated by molecular dynamic simulations and gained expertise in solid phase peptide synthesis, protein NMR, and calorimetry.
 

Benjamin Horning

Senior Scientist

Vividion

Benjamin Horning (Benji) was born in Portland, Oregon. He received his undergraduate degree in Biochemistry at the University of Oregon, working with professor Michael Haley studying metallabenzenes. He then performed graduate studies with professor David MacMillan at Princeton University, where he studied the total synthesis of the akuammiline alkaloid natural product Vincorine. His postdoctoral studies, with professor Benjamin Cravatt, focused on the development of methyltransferase photoaffinity probes. He began work at Vividion immediately following his postdoctoral studies, beginning in June of 2016. One of his many job functions at Vividion is to manage Dotmatics functionality, including user administration, form building, data analysis, project views and templates, and training.
 

Hanjo KIM, PhD

Principal Researcher

CJ Healthcare, New Drug Research Center

After Hanjo received his PhD (2004 at Yonsei University) in organic chemistry, he worked in the field of molecular modeling and cheminformatics. His previous positions include team leader at BMDRC, research staff at NUS, and head of R&D center at Equisnzaroo inc. In late 2015, he joined CJ Healthcare as a Principal Researcher, New Drug Research Center.
Currently, Hanjo’s main interest lies in support/education/deployment of molecular modeling and cheminformatics techniques for medicinal chemists. He is also developing and maintaining in-house software/scripts for specific tasks of pharmaceutical R&D process.
 

Hyunmo Yang

Principal Researcher

Chong Kun Dang

Hyunmo completed his master's degree in medicinal chemistry at Chungnam National University. He then joined Chong Kun Dang in 2006 after working at Chungnam National University's Pharmaceutical Development Research Center. In 2013, Hyunmo started studying Computer Aided Drug Design (CADD). He holds patents for a variety of new drug candidates in both phase 2 and phase 1 clinical trials and is currently working on the introduction of a compound database in Chong Kun Dang.
 

Nick Shah

Senior Scientist

DiCE Molecules

Nick joined DiCE Molecules as a Senior Scientist in June 2018 and is working with the team to leverage chemical evolution in small molecule drug discovery. Prior to DiCE, he was a member of the FLX Bio team from the company’s inception in 2015 to May 2018. He has been deeply involved in the development of multiple drug discovery assays, leading project teams, and managing multiple screening campaigns. Before FLX, Nick was a very early member of the team at Flexus Biosciences and helped discover a cancer immunotherapy molecule that resulted in an acquisition by BMS and is currently in Phase II clinical trials (BMS-986205). Nick completed his doctoral work at the University of Toronto, studying the molecular structure and mechanism of an important cancer target. He then completed a postdoctoral fellowship at Stanford University, working in the Weis and Herschlag labs studying the mechanistic enzymology of a complex motor protein involved in neurotransmission.
 

Steven Wesolowski

Senior Director of Computational Science

Xenon Pharmaceuticals

Steve Wesolowski is currently senior director of computational science at Xenon Pharmaceuticals. Previously he served as a director and project leader within the virtual Neuroscience Innovative Medicines Unit at AstraZeneca Pharmaceuticals. He was head of computational chemistry at AZ in the infection division as well as the psychiatry division prior to being recruited to join the Cambridge neuroscience team. He earned his Ph.D. in chemistry with Prof. Fritz Schaefer and was an NIH postdoctoral fellow at Yale University under Prof. Bill Jorgensen. His previous work in neuroscience has included the molecular design of AZD5213, and he led the chemistry team that advanced AZD4451. He also co-developed an industry-leading platform for high-throughput determination of absolute stereochemistry utilizing vibrational circular dichroism. Steve is the author of more than 50 publications and is a co-inventor of three compounds in clinical trials.
 

Jim Heddles

former Senior IT Manager at Sanofi and Icagen

5P Innovations

Jim Heddles grew up in Alaska and Colorado. After earning a degree in Electrical Engineering he worked briefly in the computer industry and then ended up managing a small publishing business in France for a few years. He then joined the pharmaceutical research facility of Marion Merrell Dow in Strasbourg, France. He has enjoyed 25+ years working in almost every area of research IT and informatics at the satellite research sites in Strasbourg and then in Tucson Arizona, as the company grew through mergers and acquisitions to become Sanofi. He has over ten years experience with Dotmatics products with a focus on integrated small molecule discovery. Jim most recently had the privilege of leading a phenomenal team through a complete rebuild of architecture, systems and applications after the acquisition of the Tucson facility by Icagen. His passion is to help companies understand their workflows and data needs and adopt the most appropriate tools to enable excellent decision making for drug discovery.
 

Juan Luengo, PhD

Vice President Drug Discovery Research

Prelude Therapeutics

Juan is Founding Scientist and Vice President of Drug Discovery Research Director at Prelude Therapeutics, a startup company located in Delaware, USA. Before joining Prelude, Juan worked for 27 years at GSK, where he was Head of Chemistry in the Cancer Epigenetics group. At GSK, Juan has managed the progression of several compounds into clinical studies in a number of therapeutic areas, including Oncology, MusculoSkeletal and Cardiovascular diseases. Most notably Juan was one of the inventors of Promacta (eltrombopag), and successfully led the program that resulted in its approval as the first-in-class TPO Receptor agonist for the treatment of ITP-related thrombocytopenia. Juan holds a Ph.D. degree in Organic Chemistry from the University of Michigan and did postdoctoral research at Stanford University.
 

Josh Lichtman

Senior Scientist

NGM Biopharmaceuticals

NGM Bio is a research-driven, clinical stage biopharmaceutical company with a drug discovery platform designed to generate a pipeline of first-in-class biologic drug candidates. For two years, Dr. Lichtman has been a scientist in the Target Discovery and Validation group at NGM Bio where he conducts early stage research into novel immuno-oncology targets. His role includes the development of immune assays, the application of computational biology, and the implementation of proteomics technologies to these ends. He is also part of the small team tasked with the selection and onboarding of the Dotmatics ELN/LIMS platform. Prior to working at NGM, Josh completed his PhD at Stanford University where he studied host-microbiome interactions in the gastrointestinal tract using mass spectrometry-based proteomics in the labs of Drs. Josh Elias and Justin Sonnenburg.
 

Brian Cook

Director

Vividion

Brian was born in Great Falls, MT. He completed his undergraduate degree in Chemistry from Carleton College in Northfield, MN working with professor David Alberg. He then went on to get his Ph.D. at the University of California at Berkeley under professor Carolyn Bertozzi. His research there focused on carbohydrate sulfotransferases involved in the immune response. Brian started work at Boehringer Ingelheim Pharma Inc starting in 2002 and worked there for 15 years on a variety of research projects in the Immunology and Cardiovascular therapeutic areas. In October of 2017, he started his current position at Vividion as a director in the chemistry department.
 

Jim Heddles

former Senior IT Manager at Sanofi and Icagen

5P Innovations

Jim Heddles grew up in Alaska and Colorado. After earning a degree in Electrical Engineering he worked briefly in the computer industry and then ended up managing a small publishing business in France for a few years. He then joined the pharmaceutical research facility of Marion Merrell Dow in Strasbourg, France. He has enjoyed 25+ years working in almost every area of research IT and informatics at the satellite research sites in Strasbourg and then in Tucson Arizona, as the company grew through mergers and acquisitions to become Sanofi. He has over ten years experience with Dotmatics products with a focus on integrated small molecule discovery. Jim most recently had the privilege of leading a phenomenal team through a complete rebuild of architecture, systems and applications after the acquisition of the Tucson facility by Icagen. His passion is to help companies understand their workflows and data needs and adopt the most appropriate tools to enable excellent decision making for drug discovery.
 

Benjamin Horning

Senior Scientist

Vividion

Benjamin Horning (Benji) was born in Portland, Oregon. He received his undergraduate degree in Biochemistry at the University of Oregon, working with professor Michael Haley studying metallabenzenes. He then performed graduate studies with professor David MacMillan at Princeton University, where he studied the total synthesis of the akuammiline alkaloid natural product Vincorine. His postdoctoral studies, with professor Benjamin Cravatt, focused on the development of methyltransferase photoaffinity probes. He began work at Vividion immediately following his postdoctoral studies, beginning in June of 2016. One of his many job functions at Vividion is to manage Dotmatics functionality, including user administration, form building, data analysis, project views and templates, and training.
 

Diane Geraghty

Project Coordinator

C4X Discovery Ltd

Diane joined C4X Discovery in 2017 as a project coordinator where she is involved in the project management and outsourcing coordination across the company. As a virtual drug discovery company, C4X works with many outsourcing partners: Diane coordinates this work, and oversees all the data management to ensure all data received from external partners is up to date and readily available. Prior to working at C4X, Diane achieved a PhD from the University of Nottingham and then worked as a synthetic chemist for 5 years at Peakdale Molecular (now Concept Life Sciences).
 

Josh Lichtman

Senior Scientist

NGM Biopharmaceuticals

NGM Bio is a research-driven, clinical stage biopharmaceutical company with a drug discovery platform designed to generate a pipeline of first-in-class biologic drug candidates. For two years, Dr. Lichtman has been a scientist in the Target Discovery and Validation group at NGM Bio where he conducts early stage research into novel immuno-oncology targets. His role includes the development of immune assays, the application of computational biology, and the implementation of proteomics technologies to these ends. He is also part of the small team tasked with the selection and onboarding of the Dotmatics ELN/LIMS platform. Prior to working at NGM, Josh completed his PhD at Stanford University where he studied host-microbiome interactions in the gastrointestinal tract using mass spectrometry-based proteomics in the labs of Drs. Josh Elias and Justin Sonnenburg.
 

Adrian Brüngger

Head of Discovery Informatics

Basilea Pharmaceutica International

Adrian Brüngger studied computer science at the Swiss Federal Institute of Technology (ETH Zürich). In 1997, he got his PhD in game theory and combinatorial optimization from the same institute. He then joined Novartis for a post doc where he developed a web based bioinformatics workbench for molecular biology. In 1999, he became a laboratory head in cancer research at Novartis to lead a comparative genomics projects, develop algorithms for gene expression analysis and support target and hit finding for anti-cancer programs. In 2003 he moved to the high throughput screening (HTS) department at Novartis where he designed visualization tools to explore data from HTS campaigns. In 2004 he became Head of Discovery Informatics at Basilea Pharmaceutica International. With his group, he is responsible for all aspects of scientific computing, data management and data mining, computer aided drug design, bioinformatics, cheminformatics, and logistics support.
 

Marco Pacchiani

Project Manager, R&D

Firmenich S.A.

Marco Pacchiani is a passionate project manager within Firmenich R&D department. Currently Director of Strategic Planning & Knowledge Management, he is responsible for the innovation project management office as well as global strategic research operations and alliances.

With a Master’s degree in Information systems and a Minor in Economics from Geneva University, he started his career in 2002 at Firmenich implementing global financial systems, developing financial models, statistical sales forecasting systems and reengineering global corporate financial processes.

Transitioning to Firmenich Research department, he implemented the Innovation project management office based on Stage-Gate methodology to enable strategic planning and drive portfolio decision making based on Monte-Carlo risk simulations. In addition he manages key strategic research discovery projects requiring multi-disciplinary and global teams.

Within his knowledge management responsibilities, he has initiated datamining and artificial intelligence activities within Firmenich. The team focuses on olfaction inference, perfumery optimization and enables receptor-based high throughput screening activities.
 

Diane Geraghty

Project Coordinator

C4X Discovery Ltd

Diane joined C4X Discovery in 2017 as a project coordinator where she is involved in the project management and outsourcing coordination across the company. As a virtual drug discovery company, C4X works with many outsourcing partners: Diane coordinates this work, and oversees all the data management to ensure all data received from external partners is up to date and readily available. Prior to working at C4X, Diane achieved a PhD from the University of Nottingham and then worked as a synthetic chemist for 5 years at Peakdale Molecular (now Concept Life Sciences).
 

Josh Lichtman

Senior Scientist

NGM Biopharmaceuticals

NGM Bio is a research-driven, clinical stage biopharmaceutical company with a drug discovery platform designed to generate a pipeline of first-in-class biologic drug candidates. For two years, Dr. Lichtman has been a scientist in the Target Discovery and Validation group at NGM Bio where he conducts early stage research into novel immuno-oncology targets. His role includes the development of immune assays, the application of computational biology, and the implementation of proteomics technologies to these ends. He is also part of the small team tasked with the selection and onboarding of the Dotmatics ELN/LIMS platform. Prior to working at NGM, Josh completed his PhD at Stanford University where he studied host-microbiome interactions in the gastrointestinal tract using mass spectrometry-based proteomics in the labs of Drs. Josh Elias and Justin Sonnenburg.
 

Robert Heald

Head of Chemistry

Artois Pharma

Robert has been Head of Chemistry for Artios Pharma, a small biotech focussed on the discovery and development of DNA damage response (DDR) inhibitors for the treatment of cancer, for nearly two years. Prior to Artios he was Director of Chemistry at Argenta (now CRL) where he worked for 13 years on collaborative drug discovery projects and briefly Head of Chemistry at Kesios Therapeutics.
 

Dan Leggate

Biochemist

Storm Therapeutics

I joined Storm Therapeutics in August 2016 where my focus has been on developing assays to measure the activity of RNA-modifying enzymes. Prior to this, I have worked at companies including Cellzome, BioFocus and several small start-ups. My involvement in drug discovery spans over 15 years, mostly in the area of assay development and HTS, working across a range of novel and established target classes. I am a biochemist by training, obtaining an MA and PhD from the University of Cambridge.
 

Jennifer McKelvie, PhD

Scientific Operations Lead

Cancer Research UK Ltd

Jennifer joined CRUK’s Therapeutic Discovery Laboratories (CRUK-TDL, formerly CRT-DL) in 2011 as an Assay Development and Compound Profiling Scientist before moving to her current role as Scientific Operations Lead in 2015. Prior to joining CRUK-TDL Jennifer obtained an MChem and a PhD in Chemistry at the University of Southampton. Jennifer is responsible for defining and implementing Data Management strategy at CRUK-TDL, within both the research and operational functions of the business.
 

Diane Geraghty

Project Coordinator

C4X Discovery Ltd

Diane joined C4X Discovery in 2017 as a project coordinator where she is involved in the project management and outsourcing coordination across the company. As a virtual drug discovery company, C4X works with many outsourcing partners: Diane coordinates this work, and oversees all the data management to ensure all data received from external partners is up to date and readily available. Prior to working at C4X, Diane achieved a PhD from the University of Nottingham and then worked as a synthetic chemist for 5 years at Peakdale Molecular (now Concept Life Sciences).
 

Magnus Winnerstam

Lab Data Manager

Alligator Bioscience

With a background as a Molecular Biologist and many years of hands on experience from the lab (screening, assay development, phage display etc.) and a flair for the technical side of the lab I have gained much needed experience for my role as the Laboratory Data Manager at Alligator Bioscience where I manage all IT-related activities in the laboratory.

With several years of experience and responsibility of our legacy ELN-systems I am currently leading the setup and implementation project of our new ELN system from Dotmatics. I am also responsible for the in-house database solution from Dotmatics and its implementation in Research and Development activities.
 

Inhee Choi, RPh, PhD

Senior Researcher, Bioinformatics Group

Institut Pasteur Korea (IPK)

Inhee Choi is highly experienced in computational aided drug design with a pharmacist background. She has a PhD in computational aided drug design from College of Pharmacy, Ewha Womans University in Korea and completed her postdoctoral training at the National Institute of Health (NIH), Maryland, USA. Inhee joined Institut Pasteur Korea (IPK) in 2010 upon returning to Korea. She continues to be actively involved in various bio-cheminformatics research projects. She manages and organises chemical and biological data information within her groups in the graduate school, NIH, and IPK.
 

Bradley Doak, PhD

Postdoctoral Research Scientist

Monash University

Brad completed a PhD in Synthetic Medicinal Chemistry at MIPS under the supervision of Martin Scanlon and Jamie Simpson in the area of fragment-based drug design. He then undertook postdoctoral training with Jan Kihlberg at Uppsala University, Sweden, looking at drug discovery beyond the rule of 5 with particular attention on macrocycles. Brad then returned to Monash University with the formation of the Monash Fragment Platform to continue working on fragment-based drug design, particularly early hit to lead development. Brad’s interests include medicinal chemistry and chemoinformatics in fragment development, particularly in the development of libraries. Brad’s talk will focus on the work currently undertaken on the development and design of libraries for early stages of development in fragment-based drug design, focusing on the use of designed generic reagent libraries for development when little to no structural information is available.
 

Wolfgang Jarolimek

Head of Drug Discovery

Pharmaxis

Wolfgang joined Pharmaxis in September 2010 as Manager in vitro Pharmacology and was appointed Head Drug Discovery in August 2012.
He has more than 15 years’ experience in pharmaceutical drug discovery and has published more than 30 peer reviewed articles. From 2002 to 2010 Wolfgang was Director of Assay Development and Compound Profiling at the GlaxoSmithKline Center of Excellence in Drug Discovery in Verona, Italy. In addition to chairing early drug discovery efforts locally he also had global responsibilities for ion channel screening and implementing safety-related screening. From 1998 to 2002 he worked at the Neuroscience Center of Merck, Sharp and Dohme in Harlow, England, as Senior Research Scientist in the electrophysiology group. Wolfgang previously spent 8 years as post-doc at the Max-Plank Institute in Munich, Germany; Baylor College of Medicine, Houston, Texas; Rammelkamp Center, Cleveland Ohio; and University of Heidelberg, Germany.
Wolfgang holds a BSc in Pharmacy and a PhD from the University of Saarbrücken, Germany. In 1997 he became Assistant Professor in Physiology at the University of Heidelberg, Germany.
 

Guilhem Morra

Science Systems Analyst

Plant and Food Research

I have a background in heterogeneous catalysis and high throughput screening. I hold an MSc from École Centrale de Lyon and a PhD in Chemistry from Université Claude Bernard in France. I have worked for 8 years with Johnson Matthey (UK) where I was helping our Teesside research centre with scientific data management. I have started with Plant & Food Research, New Zealand biggest Crown Research Institute in November 2016 to manage the implementation of Dotmatics across the institute.
 

Rebecca Moss

Manager, Research Technologies

Cancer Therapeutics CRC (Ctx)

Rebecca has a background in high throughput screening and data management. She holds a BSc in Applied Biology/Biotechnology (Hons) from RMIT University Melbourne. Rebecca has worked at the WEHI for 16 years and has been involved with Cancer Therapeutics (CTx) since 2008 when an electronic laboratory notebook was first introduced.

Rebecca is responsible for developing and maintaining the CTx eResearch platform, which includes the infrastructure, data systems and the applications. The eResearch Platform hosts applications such as Atlassian, SharePoint and Dotmatics. These tools facilitate the analysis and reporting of research data generated at all stages of the drug discovery pipeline.

Rebecca’s talk will focus on CTx's journey to Dotmatics and will highlight current workflows and customised features that have become essential to the data management of their successful drug discovery program.
 

Grant Stuchbury

Senior Biologist

Qeddi

With a background in neurobiology and oncology, I have been involved in small molecule drug discovery for the past 8 years. My first post-doctoral position was at Griffith University, as part of the Cancer Therapeutics CRC (CTx), where I developed and performed high throughput screening campaigns, with a focus on high content imaging. In my current role as Senior Biologist at QEDDI, I established the biology laboratory and now lead the team in designing, developing and validating robust, reliable and relevant biological assays for both high throughput screening and ongoing small molecule development.
 

Inhee Choi, RPh, PhD

Senior Researcher, Bioinformatics Group

Institut Pasteur Korea (IPK)

Inhee Choi is highly experienced in computational aided drug design with a pharmacist background. She has a PhD in computational aided drug design from College of Pharmacy, Ewha Womans University in Korea and completed her postdoctoral training at the National Institute of Health (NIH), Maryland, USA. Inhee joined Institut Pasteur Korea (IPK) in 2010 upon returning to Korea. She continues to be actively involved in various bio-cheminformatics research projects. She manages and organises chemical and biological data information within her groups in the graduate school, NIH, and IPK.
 

Tatiana Guzzo

Head Of Chemistry Lab

C4T

Dr Tatiana Guzzo has a Master’s Degree in Industrial Chemistry (110/110), attained at the University of Rome “Sapienza”. At C4T since 2006, she is a senior research scientist with proven expertise in Organic Synthesis and Medicinal Chemistry. She is project Leader of C4T research services to major pharma companies and of key Med Chem Proprietary Projects (e.g., FP7 – Florinash; MIUR – IVASCOMAR). She is co-inventor of a new class of CB2 modulators (C4T Patent). She is in charge of the scientific management of the different research teams. She has been tutor of 6 stages of Organic Synthesis training. She also contributed to the implementation of C4T Platform for Advanced NMR studies for industrial application (i.e., DOSY-NMR; isotope NMR; 2D-NMR). She gave relevant contribution to the implementation of C4T Quality & Safety Management System (ISO 9001 and OHSAS 18001). As “Cultore della materia”, she is teaching assistant for the course in Combinatorial Chemistry and Drug Design at the Chemistry Department of the University of Rome “Tor Vergata”. Since 2015 in charge of the Training Module in <Principles of drug discovery> for the II Level Master: “Sviluppo preclinico e clinico del farmaco: aspetti tecnico-scientifici, regolatori ed etici” at Università Cattolica del Sacro Cuore – Rome.
 

Bernard Lesch

International Research Project Lead

Grünenthal Innovation

Leading multidisciplinary teams to achieve the goals is Bernard's passion. With more than ten years experience in the pharmaceutical industry, Bernhard offers a strong background in synthetic organic chemistry, project managament and medicinal chemistry. Besides process development and lead finding/optimzation projects in medicinal chemistry, he has participated in and managed IT infrastructure projects, demonstrating leadership even in unfamiliar areas.
 

Christina Majer

Head of Screening and Data Systems

Ribon Therapautics

Christina Majer is Head of Screening and Data Systems at Ribon Therapeutics where she oversees the compound management team, their database, and the primary screening of all library compounds in two different assay platforms. Her experience includes building integrated workflows from the ground up, including compound management, assay development and screening, data management, and outsourcing across multiple sites. Prior to Ribon, Christina was at Warp Drive Bio, Epizyme, Inc, and Millennium (Takeda).
 

Gary Nugent

Senior Scientific Officer

The Institute of Cancer Research

After studying Chemistry with Pharmaceutical and Forensic Sciences at the University of Bradford, Gary joined Evotec as a synthetic chemist. He then moved to Summit Plc as a medicinal chemist before swapping roles and moving into informatics data management . In 2009 he joined the CRUK Cancer Therapeutics Unit at the Institute of Cancer Research, London where he manages the Dotmatics informatics platform. Working with the multidisciplinary project teams, he is responsible for customising Dotmatics to ensure that data is easily accessed and displayed in an appropriate format.
 

Aravind Prasad

Scientist 1, Computational Chemistry

Celgene

Aravind Prasad is a Bioinformatics Scientist at Celgene in the Computational Chemistry group. He has previously worked in various capacities at major biotechnology companies as well as startups in the US and India.

At Celgene, Aravind supports New Target drug discovery efforts and is deeply involved in efforts to bring in silico technology solutions to drug discovery scientists. While he was at Avila Therapeutics, he developed the Avilomics™ covalent drug discovery platform that has successfully generated over a dozen development candidates so far. Prior to this he coordinated with a team of developers to build an Integrated Cheminformatics Expert System across global sites for a large pharma client. Aravind holds a Masters degree in Bioinformatics from Northeastern University and a bachelors degree in Electronic and Communications Engineering from Osmania University in India.
 

Jean Richardson

IT Scientist

Debiopharm International SA

Jean is an experienced Life Sciences Application Scientist analyzing business needs and implementing informatics solutions for the Research and Discovery sectors. Currently working at Debiopharm International S.A. Previously worked at Dotmatics and 15 years at Merck Serono. Trained as a physicist with a Doctor of Philosophy (Ph.D.) focused in High Energy Physics at CERN from the University of Liverpool.
 

René Van Den Bersselaar

Director, Information Technology

Debiopharm Group

Rene Van Den Bersselaar completed his degree in Biochemistry and Molecular Biology at Utrecht University, which he followed with a number of high profile IT positions at Merck Sharp and Dohme and Vivenics, before joining Debiopharm International in 2017. He is an IT entrepreneur with over 25 years of experience in the Pharmaceutical industry including R&D, Manufacturing, Engineering, Marketing & Operations and Patents. Rene enjoys shaping strategic business directions and translating these into high-level program requirements, leveraging best practice and introducing new cost effective methods and approaches to people and project portfolio management.
 

Gautam Agnihotri

Senior Director, Research Service Division

WuXi AppTec

Dr. Gautam Agnihotri has more than 18 years of experience in the pharmaceutical and biotech industry. After graduating with a Ph.D. in Biological Chemistry from the University of Minnesota, Minneapolis, he joined SmithKline Beecham (now GSK) as a post-doctoral scientist in 2000, where he worked in the area of HTS assay development for anti-infective targets. He joined NeoGenesis, Inc. in 2002 where he was part of a group that provided biochemical and cell assay support for external collaborations as well as internal discovery programs.
After NeoGenesis was acquired by Schering-Plough, he joined the HTS group of Schering-Plough in 2006, where he supervised assay development, screening, data analysis, and post-HTS followup for a wide variety of target classes from diverse disease areas in both medium throughput (96/384) and high-throughput (1536) formats.
After the acquisition of Schering-Plough by Merck, Dr. Agnihotri joined the In Vitro Pharmacology group at Merck Research Labs in Kenilworth, NJ in 2010. He led a team in the Biochemistry/Biophysics group to develop assays and determine mode of action for multiple protease targets and then moved to the Screening Operations team in 2012 where he led a team of compound management scientists, automation engineers, and biologists. He left Merck in June 2014 to join WuXi AppTec, and is currently Senior Director in the Research Service Division.
Dr. Agnihotri’s skills span the areas of biochemistry and enzymology, as well as medium and high-throughput screening, automation, data analysis and reporting. In his current role, he helped in the establishment of WuXi AppTec labs in New Jersey and is leading biochemical/biophysical assay development and optimization.
 

Michael Beluch

Lead, Digital Capability Management, Leads Discovery and Optimization

Bristol-Myers Squibb

Mike Beluch is the Lead Digital Capability Manager for the Leads Discovery & Optimization group at Bristol-Myers Squibb. Mike has worked in the chemical and pharmaceutical industries for 25 years, starting his career at the bench as a Molecular Biologist, specializing for many years in nuclear hormone receptors and cholesterol efflux pathways. In 2004, Mike transitioned to IT at BMS, advancing a 'user-perspective', while working to develop, integrate, and support applications used in Research and Discovery Biology. His responsibilities have been to support existing and emerging technologies in the High-throughput screening group via software development and third-party software integration. In 2019, Mike transitioned to a broader role as a DCM Lead for LDO, responsible for defining strategic technology road-maps and developing solution architectures for new business capabilities.
 

Johannes H. Voigt

Directory, Computational Chemistry

Foghorn Therapeutics

Johannes Voigt is Director of Computational Chemistry at Foghorn Therapeutics, where he is responsible for ligand and structure based drug design, chemoinformatics, and decision enabling tools. Prior to joining Foghorn, Dr. Voigt contributed to drug discovery projects at Schering-Plough/Merck, Gilead, and CHDI. He is co-author of over 50 publications.
 

Christina Majer

Head of Screening and Data Systems

Ribon Therapautics

Christina Majer is Head of Screening and Data Systems at Ribon Therapeutics where she oversees the compound management team, their database, and the primary screening of all library compounds in two different assay platforms. Her experience includes building integrated workflows from the ground up, including compound management, assay development and screening, data management, and outsourcing across multiple sites. Prior to Ribon, Christina was at Warp Drive Bio, Epizyme, Inc, and Millennium (Takeda).
 

Daniel McMasters

Director, Modeling & Informatics

Vertex Pharmaceuticals

Daniel McMasters is a Director in the Modeling & Informatics group at Vertex Pharmaceuticals based in Boston. His group is responsible for advancing the drug discovery projects at Vertex’s Boston research site with computational chemistry and cheminformatics. He also contributes to strategic and company-wide efforts in data visualization, predictive modeling, and in silico ADME and toxicity. Prior to Vertex, he worked from 2000 to 2016 for Merck & Co. He obtained a B.S. in chemistry from Stanford University, M.Sc. in organic chemistry from the University of Chicago, and D.Phil. in physical chemistry from the University of Basel, and did postdoctoral work at the Biographics Laboratory in Basel.
 

Gautam Agnihotri

Senior Director, Research Service Division

WuXi AppTec

Dr. Gautam Agnihotri has more than 18 years of experience in the pharmaceutical and biotech industry. After graduating with a Ph.D. in Biological Chemistry from the University of Minnesota, Minneapolis, he joined SmithKline Beecham (now GSK) as a post-doctoral scientist in 2000, where he worked in the area of HTS assay development for anti-infective targets. He joined NeoGenesis, Inc. in 2002 where he was part of a group that provided biochemical and cell assay support for external collaborations as well as internal discovery programs.
After NeoGenesis was acquired by Schering-Plough, he joined the HTS group of Schering-Plough in 2006, where he supervised assay development, screening, data analysis, and post-HTS followup for a wide variety of target classes from diverse disease areas in both medium throughput (96/384) and high-throughput (1536) formats.
After the acquisition of Schering-Plough by Merck, Dr. Agnihotri joined the In Vitro Pharmacology group at Merck Research Labs in Kenilworth, NJ in 2010. He led a team in the Biochemistry/Biophysics group to develop assays and determine mode of action for multiple protease targets and then moved to the Screening Operations team in 2012 where he led a team of compound management scientists, automation engineers, and biologists. He left Merck in June 2014 to join WuXi AppTec, and is currently Senior Director in the Research Service Division.
Dr. Agnihotri’s skills span the areas of biochemistry and enzymology, as well as medium and high-throughput screening, automation, data analysis and reporting. In his current role, he helped in the establishment of WuXi AppTec labs in New Jersey and is leading biochemical/biophysical assay development and optimization.
 

JW Feng, PhD

Director of Discovery Data Science

Denali Therapeutics Inc.

JW is passionate about applying computer science to solve problems in drug discovery. He has been leveraging expertise in software development and molecular modeling to invent new drugs to treat unmet medical needs. His passion for informatics empowers drug discovery scientists by removing both technical and behavioral barriers to organizing, sharing and analyzing data. In the last four years, JW built Denali’s molecular modeling and informatics group to support both small molecule and biotherapeutics discovery. Key contributions from his team lead to inventions of multiple drugs entering clinical trials. Prior to Denali, JW was a Scientist at Genentech supporting small molecule drug discovery. JW received bachelor of science degrees in Computer Science and Biochemistry at The Ohio State University. After college, he was seduced by the Y2K rage and joined IBM as a software engineer only to realize his true love was to apply computer science to solve problems in biology. He found that at Washington University in St. Louis where he developed a systematic ligand docking algorithm that decouples sampling and scoring. He also experimentally tested hypotheses generated by molecular dynamic simulations and gained expertise in solid phase peptide synthesis, protein NMR, and calorimetry.
 

Benjamin Horning

Senior Scientist

Vividion

Benjamin Horning (Benji) was born in Portland, Oregon. He received his undergraduate degree in Biochemistry at the University of Oregon, working with professor Michael Haley studying metallabenzenes. He then performed graduate studies with professor David MacMillan at Princeton University, where he studied the total synthesis of the akuammiline alkaloid natural product Vincorine. His postdoctoral studies, with professor Benjamin Cravatt, focused on the development of methyltransferase photoaffinity probes. He began work at Vividion immediately following his postdoctoral studies, beginning in June of 2016. One of his many job functions at Vividion is to manage Dotmatics functionality, including user administration, form building, data analysis, project views and templates, and training.
 

Donogh O'Mahony

Staff Scientist

Nektar Therapeutics

Donogh O'Mahony joined Nektar Therapeutics in 2011, where he is a Staff Scientist; currently he divides his time between new chemical entity design and synthesis, and leading the implementation effort of the Dotmatics suite within discovery research. Prior to this he worked on anti-infectives at NovaBay Pharmaceuticals, and CNS indications at Renovis (acquired by Evotec). He received his fist introduction to the power of cheminformatics solutions in 1999 upon joining SIDDCO (acquired by Discovery Partners Int’l, Inc.) where he worked in chemical library synthesis. Donogh completed BSc and PhD degrees at Imperial College London, and conducted further postdoctoral research at Montana State University Bozeman.
 

Katherine Walker

Research Associate II - Chemistry

DiCE Molecules

Katherine studied chemistry at Wesleyan University in Middletown, Connecticut and has been working at DiCE Molecules since she graduated. In her role at DiCE, she is focused on chemistry development for DNA encoded libraries. She has also been heavily involved in the implementation of Dotmatics and testing of custom Dotmatics solutions at DiCE.
 

Tanja Gellert

Chemical Technical Assistant

Morphosys AG

Tanja Gellert graduated is a Chemical Technical Assistant at Chemieschule Elhardt, Munich. Tanja has worked at different Universities firstly in the field of Genetics and later in Immunology. In 2006 she joined MorphoSys, working as a Technical Assistant in the Discovery and Alliances Unit on customer & MorphoSys own projects. Since the implementation of the integrated R&D database at MorphoSys she is also a critical contributor of the support & development team and working together with IT as a “connector” between the Lab and IT department.
 

Tanja Gellert

Chemical Technical Assistant

Morphosys AG

Tanja Gellert graduated is a Chemical Technical Assistant at Chemieschule Elhardt, Munich. Tanja has worked at different Universities firstly in the field of Genetics and later in Immunology. In 2006 she joined MorphoSys, working as a Technical Assistant in the Discovery and Alliances Unit on customer & MorphoSys own projects. Since the implementation of the integrated R&D database at MorphoSys she is also a critical contributor of the support & development team and working together with IT as a “connector” between the Lab and IT department.
 

Takayuki Kochi

Manager, Research Platform

Asahi Kasei Pharma Corporation

2000 : Department of Material and Life Science, Graduate School of Engineering, Osaka University
2000 : Hitachi Software Engineering Co., Ltd.
2013 : AsahiKasei Pharma Corporation
2018 : Manager, Research Platform, Laboratory for Medicinal Chemistry
 

Nick Shah

Senior Scientist

DiCE Molecules

Nick joined DiCE Molecules as a Senior Scientist in June 2018 and is working with the team to leverage chemical evolution in small molecule drug discovery. Prior to DiCE, he was a member of the FLX Bio team from the company’s inception in 2015 to May 2018. He has been deeply involved in the development of multiple drug discovery assays, leading project teams, and managing multiple screening campaigns. Before FLX, Nick was a very early member of the team at Flexus Biosciences and helped discover a cancer immunotherapy molecule that resulted in an acquisition by BMS and is currently in Phase II clinical trials (BMS-986205). Nick completed his doctoral work at the University of Toronto, studying the molecular structure and mechanism of an important cancer target. He then completed a postdoctoral fellowship at Stanford University, working in the Weis and Herschlag labs studying the mechanistic enzymology of a complex motor protein involved in neurotransmission.
 

Hiroshi Uchida

Manager, Synthetic Research Department

ASKA Pharmaceutical Co., Ltd.

1997:School of Pharmaceutical Sciences, University of Shizuoka, Ph.D.
1997:Teikoku Hormone MFG. Co., Ltd., Researcher, Medicinal Chemist
2005:ASKA Pharmaceutical Co., Ltd., Researcher, Medicinal Chemist
2008:ASKA Pharmaceutical Co., Ltd., Manager, Synthetic Research Department
 

Tanja Gellert

Chemical Technical Assistant

Morphosys AG

Tanja Gellert graduated is a Chemical Technical Assistant at Chemieschule Elhardt, Munich. Tanja has worked at different Universities firstly in the field of Genetics and later in Immunology. In 2006 she joined MorphoSys, working as a Technical Assistant in the Discovery and Alliances Unit on customer & MorphoSys own projects. Since the implementation of the integrated R&D database at MorphoSys she is also a critical contributor of the support & development team and working together with IT as a “connector” between the Lab and IT department.
 

Tanja Gellert

Chemical Technical Assistant

Morphosys AG

Tanja Gellert graduated is a Chemical Technical Assistant at Chemieschule Elhardt, Munich. Tanja has worked at different Universities firstly in the field of Genetics and later in Immunology. In 2006 she joined MorphoSys, working as a Technical Assistant in the Discovery and Alliances Unit on customer & MorphoSys own projects. Since the implementation of the integrated R&D database at MorphoSys she is also a critical contributor of the support & development team and working together with IT as a “connector” between the Lab and IT department.
 

Takayuki Kochi

Manager, Research Platform

Asahi Kasei Pharma Corporation

2000 : Department of Material and Life Science, Graduate School of Engineering, Osaka University
2000 : Hitachi Software Engineering Co., Ltd.
2013 : AsahiKasei Pharma Corporation
2018 : Manager, Research Platform, Laboratory for Medicinal Chemistry
 

Hiroshi Uchida

Manager, Synthetic Research Department

ASKA Pharmaceutical Co., Ltd.

1997:School of Pharmaceutical Sciences, University of Shizuoka, Ph.D.
1997:Teikoku Hormone MFG. Co., Ltd., Researcher, Medicinal Chemist
2005:ASKA Pharmaceutical Co., Ltd., Researcher, Medicinal Chemist
2008:ASKA Pharmaceutical Co., Ltd., Manager, Synthetic Research Department
 

Tanja Gellert

Chemical Technical Assistant

Morphosys AG

Tanja Gellert graduated is a Chemical Technical Assistant at Chemieschule Elhardt, Munich. Tanja has worked at different Universities firstly in the field of Genetics and later in Immunology. In 2006 she joined MorphoSys, working as a Technical Assistant in the Discovery and Alliances Unit on customer & MorphoSys own projects. Since the implementation of the integrated R&D database at MorphoSys she is also a critical contributor of the support & development team and working together with IT as a “connector” between the Lab and IT department.
 

Tanja Gellert

Chemical Technical Assistant

Morphosys AG

Tanja Gellert graduated is a Chemical Technical Assistant at Chemieschule Elhardt, Munich. Tanja has worked at different Universities firstly in the field of Genetics and later in Immunology. In 2006 she joined MorphoSys, working as a Technical Assistant in the Discovery and Alliances Unit on customer & MorphoSys own projects. Since the implementation of the integrated R&D database at MorphoSys she is also a critical contributor of the support & development team and working together with IT as a “connector” between the Lab and IT department.
 

Mr. Jae Sung Hwang

Research Scientist

Dong-A ST

Jaesung Hwang studied a computation chemistry for his masters degree in Soongsil University, Seoul, Korea. He started his career at JW JoongWae research center in 2003 in field of molecular modeling and computer-aided drug discovery (CADD) and he joined current Dong-A ST research center in 2010 as senior research scientist in discovery technology research lab. Currently, he has been focusing on more potent & selective inhibitor design with published x-ray and docking ADME/T prediction as computer-aided drug design (CADD) roles and is responsible for in-house library database system management of same research center
 

Hanjo KIM, PhD

Principal Researcher

CJ Healthcare, New Drug Research Center

After Hanjo received his PhD (2004 at Yonsei University) in organic chemistry, he worked in the field of molecular modeling and cheminformatics. His previous positions include team leader at BMDRC, research staff at NUS, and head of R&D center at Equisnzaroo inc. In late 2015, he joined CJ Healthcare as a Principal Researcher, New Drug Research Center.
Currently, Hanjo’s main interest lies in support/education/deployment of molecular modeling and cheminformatics techniques for medicinal chemists. He is also developing and maintaining in-house software/scripts for specific tasks of pharmaceutical R&D process.
 

Soolki Kwon

Senior Scientist

Yuhan

1998~2005 Kyunghee University College of Life Science, Genetic engineering, BS
2006~2008 Yonsei University Graduate School of Medicine, Cell biology & Pharmacology, MS
2008~2010 Yonsei University, Department of Biochemistry & Molecular Biology, Research Scientist
2010~2016 CrystalGenomics R&D Institute, Discovery Biology, Senior Research Scientist
2016~ Yuhan R&D Institute, Chemistry&Chemical Biology, Senior Scientist
 

Robert Coner

Associate Director, R&D Informatics

Peloton Therapeutics

Robert “Bob” Coner is currently Associate Director, R&D Informatics at Peloton Therapeutics. Bob previously worked for Pfizer for a decade and prior to that Eli Lilly. He implemented the Dotmatics system at Peloton Therapeutics in the early days of the company. Peloton Therapeutics is a clinical-stage biotechnology company that discovers and develops first-in-class, small molecule cancer therapies targeting unexploited molecular vulnerabilities.
 

George Lane

Research Informatics in Structural Chemistry

Gilead Sciences

George Lane earned a Bachelor of Science degree in Chemistry from the University of Rochester in 1997. His first position was at the combi chem library synthesis company SIDDCO where preparing electronic registration files to match the physical synthesis plates was his introduction to chemoinformatics. That led to a position at Sunesis, with more library registration and a variety of other responsibilities. At Gilead, George was instrumental in attempts to implement web based project analysis and view interfaces and identified and led to the adoption of Dotmatics as a research wide tool in 2009. Among George’s many other responsibilities are managing the data warehousing protocols and registration systems for the drug discovery programs at Gilead.
 

Aravind Prasad

Scientist 1, Computational Chemistry

Celgene

Aravind Prasad is a Bioinformatics Scientist at Celgene in the Computational Chemistry group. He has previously worked in various capacities at major biotechnology companies as well as startups in the US and India.

At Celgene, Aravind supports New Target drug discovery efforts and is deeply involved in efforts to bring in silico technology solutions to drug discovery scientists. While he was at Avila Therapeutics, he developed the Avilomics™ covalent drug discovery platform that has successfully generated over a dozen development candidates so far. Prior to this he coordinated with a team of developers to build an Integrated Cheminformatics Expert System across global sites for a large pharma client. Aravind holds a Masters degree in Bioinformatics from Northeastern University and a bachelors degree in Electronic and Communications Engineering from Osmania University in India.
 

Ray Boffey

Senior Medicinal Chemist

Domainex

Ray Boffey: Ray is a Medicinal Chemist Group Leader with 18 years experience and joined Domainex Ltd, a UK-based drug discovery CRO in 2010. He has lead numerous medicinal chemistry projects including target selection, HTS, hit identification and lead optimisation through to pre-candidate selection. Ray’s prior experience covers both academic and private sectors; including Argenta Discovery (Team leader, 6 years working with GSK, Lundbeck and Aventis), Lectus Therapeutics Ltd (senior medicinal chemist, 3 years) and Oxford Glycoscience (senior scientist, 2 years).
 

Jonny Wray

Head of Discovery Informatics

e-Therapeutics plc.

Jonny Wray is the Head of Discovery Informatics at e-Therapeutics and responsible for the conceptual formulation of their network-driven drug discovery approach and leads the team of computational experts responsible for the implementation of their in-silico discovery platform. He has over 25 years’ experience in the application of mathematical and computational techniques to the modelling and analysis of biological systems. Following post-doctoral work at the Neurosciences Institute moved into the biotechnology industry with positions of increasing responsibilities in bioinformatics and drug discovery informatics at Clontech and, most recently, Five Prime Therapeutics. Holds a PhD in computational biology from Newcastle University Medical School.
 

Alessio Barilli

Principal Scientist

Aptuit

Alessio Barilli graduated in Chemistry in 2001 at the University of Milan where he later attained his PhD in Organic Chemistry in 2005. Alessio started his career at Nikem Research, a medium sized CRO in Milan, as a junior Researcher, and worked there from 2005 to 2012. On joining Aptuit in 2012,he worked on multiple projects with diverse clients at the Medicinal Chemistry Department.
 

Michael Beckmann

Group IT – Business Account Management

Clariant International Ltd.

Michael Beckmann works for Clariant Group IT in Switzerland. Michael has a strong chemistry background and worked for more than 15 years in analytical and R&D focused labs. For the past 20 years Michael has been working for Clariant IT in different roles and responsibilities.

In his current role as an IT Business Account Manager, Michael is managing all R&D related IT requirements. 7 years ago he identified the issues resulting from a high diverse setup of applied IT tools in R&D. As a consequence and as part of the strategic alignment between IT and the R&D units, a fully-fledged requirement analysis for an ELN was conducted in 2016, and starting 2017 Clariant is about to complete the global Dotmatics ELN implementation project by end of 2020. Michael is supporting this project and takes care that the program to modernize IT in R&D leads to seamless processes, paperless workplaces, real knowledge management and a fully connected environment that is mobile enabled in order to generate more lab bench-time.
 

Michael Beluch

Lead, Digital Capability Management, Leads Discovery and Optimization

Bristol-Myers Squibb

Mike Beluch is the Lead Digital Capability Manager for the Leads Discovery & Optimization group at Bristol-Myers Squibb. Mike has worked in the chemical and pharmaceutical industries for 25 years, starting his career at the bench as a Molecular Biologist, specializing for many years in nuclear hormone receptors and cholesterol efflux pathways. In 2004, Mike transitioned to IT at BMS, advancing a 'user-perspective', while working to develop, integrate, and support applications used in Research and Discovery Biology. His responsibilities have been to support existing and emerging technologies in the High-throughput screening group via software development and third-party software integration. In 2019, Mike transitioned to a broader role as a DCM Lead for LDO, responsible for defining strategic technology road-maps and developing solution architectures for new business capabilities.
 

Andrea Bernardelli

Principal Scientist

Aptuit

Andrea Bernardelli graduated in 2008 with a degree in Industrial Chemistry from the University of Padua. Later that year he started his career at CIVEN as a Junior Scientist in the field of nanotechnologies (synthesis of silica nanoparticles and their characterisation/application). Andrea joined GlaxoSmithKline in 2009 as NMR Spectroscopy Associate Scientist and Aptuit in 2011 as NMR Spectroscopy Scientist, always working in the field of Spectroscopy techniques with involvement in several projects. Andrea has proven expertise in NMR Spectroscopy both in regulated (GMP) and non-regulated areas.
 

Inhee Choi, RPh, PhD

Senior Researcher, Bioinformatics Group

Institut Pasteur Korea (IPK)

Inhee Choi is highly experienced in computational aided drug design with a pharmacist background. She has a PhD in computational aided drug design from College of Pharmacy, Ewha Womans University in Korea and completed her postdoctoral training at the National Institute of Health (NIH), Maryland, USA. Inhee joined Institut Pasteur Korea (IPK) in 2010 upon returning to Korea. She continues to be actively involved in various bio-cheminformatics research projects. She manages and organises chemical and biological data information within her groups in the graduate school, NIH, and IPK.
 

Mattias Levin

Research Scientist

Alligator Biosciences

Mattias Levin has a Masters degree in Biotechnology as well as a PhD in Immunotechnology from Lund University, Sweden. He has extensive experience in antibody engineering, with focus on library technologies and discovery of novel antibody based molecules. Mattias joined Alligator Biosciences in 2015 and holds responsibilities within discovery and development of new candidates that are part of Alligator's pipeline of antibody based immuno-oncology drugs.
 

Michela Terdoslavich

Scientist, Cell Assay Development, Biotherapeutic Discovery Division

Rottapharm Biotech.

Michela Terdoslavich, joined Rottapharm Biotech in 2009 and currently serves as Cell Assay Development Scientist in the Biotherapeutic Discovery Division. Michela holds a Doctoral Degree in Chemistry and Pharmaceutical Technology, with the qualification in Pharmacology and Drug Therapy and a PhD in Bio-Molecular Science from the University of Trieste. She started work in the Antibody Discovery field during her PhD and gained further experience at the University of Groningen (The Netherlands) and the Blood Transfusion Centre of Ljubljana (Slovenia), where she was entirely dedicated to the study of antibody screening methods and related in-vitro Assays Development. She co-authored several scientific papers as the result of academic collaborations.

Since 2015, she has been actively involved in collaborating with Dotmatics to develop an informatics solution to track data and to monitor biotherapeutics discovery projects. She believes that the future challenge for the Biotherapeutic Discovery resides in gaining competitive advantages from the informatics solutions provided by Dotmatics as a tool for the “best informed decision”.
 

Allan Jordan

Head of Chemistry

Cancer Research, UK

Dr Allan Jordan joined the CRUK Manchester Institute Drug Discovery Unit in July 2009 as Head of Chemistry. He gained a BSc in Chemistry from UMIST in 1993 and, after a short spell as a teaching assistant in Arizona, he returned to UMIST to conduct post-graduate research into anticancer natural products. Following post-doctoral work at the University of Reading, he joined RiboTargets in Cambridge (now Vernalis) where he worked on a number of therapeutic areas at various stages of the research pipeline. He has been involved in the delivery of seven pre-clinical candidates, of which three have successfully entered human clinical trials.

In his present role, alongside responsibilities for management of the chemistry team and progression of the drug discovery portfolio, he oversees the group’s capabilities in structural biology, computational chemistry and chemoinformatics. With a strong focus on data integrity and accessible approaches to enhanced integration, the team were awarded an S-Lab Effective Lab award for IT and Informatics Integration in 2013.

He is also passionately involved in science communication and research engagement with the general public, fundraisers and technology providers through direct contact and the broadcast media. In 2014 he was a recipient of a Cancer Research UK “Flame of Hope” award (the charity’s highest award for voluntary services) for his contributions to research engagement on behalf of the charity.
 

Rena Nishizawa, PhD

Medicinal Chemistry Research Laboratories

Ono Pharmaceutical Co., LTD.

Dr. Rena Nishizawa initiated her professional work at Ono Pharmaceutical Co., Ltd since 1999. She has more than 15 year experience in drug discovery and project leadership against GPCRs, ion channels and kinases. Her research is aimed to identify promising small molecule compounds which have the power of improving someone’s life.
 

Fredrik Rahm

Principal Scientist

Sprint Bioscience

Fredrik has a background in synthetic organic chemistry with a PhD in organic chemistry from Royal Institute of Technology (KTH) in Stockholm (2003). After post-doctoral studies in Brisbane and Stockholm, he joined AstraZeneca in 2005. At AstraZeneca, Fredrik worked in the Lead Generation section where his key role was as a chemistry project leader, managing drug discovery projects in the hit-to-lead phase. In late 2011, he joined Sprint Bioscience as a Principal Scientist, Medicinal Chemistry. At Sprint Bioscience, Fredrik focuses on driving fragment-based drug discovery projects in the pre-clinical phase and he’s also responsible for taking care of and developing the cheminformatics platform.
 

Allan Jordan

Head of Chemistry

Cancer Research, UK

Dr Allan Jordan joined the CRUK Manchester Institute Drug Discovery Unit in July 2009 as Head of Chemistry. He gained a BSc in Chemistry from UMIST in 1993 and, after a short spell as a teaching assistant in Arizona, he returned to UMIST to conduct post-graduate research into anticancer natural products. Following post-doctoral work at the University of Reading, he joined RiboTargets in Cambridge (now Vernalis) where he worked on a number of therapeutic areas at various stages of the research pipeline. He has been involved in the delivery of seven pre-clinical candidates, of which three have successfully entered human clinical trials.

In his present role, alongside responsibilities for management of the chemistry team and progression of the drug discovery portfolio, he oversees the group’s capabilities in structural biology, computational chemistry and chemoinformatics. With a strong focus on data integrity and accessible approaches to enhanced integration, the team were awarded an S-Lab Effective Lab award for IT and Informatics Integration in 2013.

He is also passionately involved in science communication and research engagement with the general public, fundraisers and technology providers through direct contact and the broadcast media. In 2014 he was a recipient of a Cancer Research UK “Flame of Hope” award (the charity’s highest award for voluntary services) for his contributions to research engagement on behalf of the charity.
 

Rena Nishizawa, PhD

Medicinal Chemistry Research Laboratories

Ono Pharmaceutical Co., LTD.

Dr. Rena Nishizawa initiated her professional work at Ono Pharmaceutical Co., Ltd since 1999. She has more than 15 year experience in drug discovery and project leadership against GPCRs, ion channels and kinases. Her research is aimed to identify promising small molecule compounds which have the power of improving someone’s life.
 

Fredrik Rahm

Principal Scientist

Sprint Bioscience

Fredrik has a background in synthetic organic chemistry with a PhD in organic chemistry from Royal Institute of Technology (KTH) in Stockholm (2003). After post-doctoral studies in Brisbane and Stockholm, he joined AstraZeneca in 2005. At AstraZeneca, Fredrik worked in the Lead Generation section where his key role was as a chemistry project leader, managing drug discovery projects in the hit-to-lead phase. In late 2011, he joined Sprint Bioscience as a Principal Scientist, Medicinal Chemistry. At Sprint Bioscience, Fredrik focuses on driving fragment-based drug discovery projects in the pre-clinical phase and he’s also responsible for taking care of and developing the cheminformatics platform.
 

Inhee Choi, RPh, PhD

Senior Researcher, Bioinformatics Group

Institut Pasteur Korea (IPK)

Inhee Choi is highly experienced in computational aided drug design with a pharmacist background. She has a PhD in computational aided drug design from College of Pharmacy, Ewha Womans University in Korea and completed her postdoctoral training at the National Institute of Health (NIH), Maryland, USA. Inhee joined Institut Pasteur Korea (IPK) in 2010 upon returning to Korea. She continues to be actively involved in various bio-cheminformatics research projects. She manages and organises chemical and biological data information within her groups in the graduate school, NIH, and IPK.
 

Kwan Hoon Hyun, PhD

Senior Principal Scientist

Yuhan Research Institute

Kwan Hoon Hyun did his undergraduate and graduate work at Inha university in Korea. His thesis work with prof. Chan Kyung Kim focused in computer aided molecular and drug design including 3D-QSAR, molecular docking for virtual screening.

From 2005 to 2006 he worked as a postdoctoral researcher in the field of molecular modeling at The Scripps Research Institute with prof. Ruben Abagyan, founder of ICM modeling program.

In 2006, after postdoctoral studies, he joined Crystalgenomics as a principal scientist. He experienced for structure based drug discovery platform techknowledge based on x-ray crystal structure determination and virtual screening for hit and lead compounds. Since 2009, he has been working as a senior principal scientist in computer-aided drug design team at Yuhan research institute. His job covers management of new drug information system and supporting medicinal chemistry group using computer-aided drug design techknowledge.
 

Mr. Kideok Kim

Research Scientist

Institut Pasteur Korea (IPK)

Kideok Kim studied biochemistry and graduated with a master degree from Inha University. He started his career at Gachon Clinical Trial Center in 2008 as a bench scientist, working in pre-clinical trial drug discovery for in-vitro pharmacology, in-vitro ADME-Tox, and in-vivo pharmacokinetics as well as managing the company wide Laboratory Information Management System in accordance with GLP guidelines. He joined Institute Pasteur Korea in 2011, and is now the automation specialist in the Automation & Logistics Management Group, where he is responsible for the high content technology instruments and the automated robotics systems. Furthermore he also manages the chemical and biological samples at IPK as well as the database system, where he developed a LIMS solution for the chemical and RNAi libraries. Kideok is also one of the founders of the Laboratory Robotics Interest Group – Korea, which started in 2016.
 

Michael Beluch

Lead, Digital Capability Management, Leads Discovery and Optimization

Bristol-Myers Squibb

Mike Beluch is the Lead Digital Capability Manager for the Leads Discovery & Optimization group at Bristol-Myers Squibb. Mike has worked in the chemical and pharmaceutical industries for 25 years, starting his career at the bench as a Molecular Biologist, specializing for many years in nuclear hormone receptors and cholesterol efflux pathways. In 2004, Mike transitioned to IT at BMS, advancing a 'user-perspective', while working to develop, integrate, and support applications used in Research and Discovery Biology. His responsibilities have been to support existing and emerging technologies in the High-throughput screening group via software development and third-party software integration. In 2019, Mike transitioned to a broader role as a DCM Lead for LDO, responsible for defining strategic technology road-maps and developing solution architectures for new business capabilities.
 

Karina Chmielewski

Platform Informatics

Third Rock Ventures

Karina joined Third Rock Ventures in 2015 as a consultant, platform informatics. Her primary focus has been development, implementation and refinement of technology roadmaps for companies across TRV portfolio with a focus on the identification and integration of drug discovery and development technology platforms. Over the last 18 months, Karina has lead informatics platform build at Relay Therapeutics and is currently managing platform build at Goldfinch Bio and Tango Therapeutics. Prior to joining Third Rock, Karina served as the head of the metabolomics platform development to support translational efforts and clinical trials at Agios Pharmaceuticals. Before Agios, Karina worked at TransForm Pharmaceuticals, where she lead development of technology platforms focused on data management, analytics, and automation. Karina holds a B.A and M.S. in Chemistry from Boston University, as well as a M.S. in Computer Science from Boston University.
 

Ping Du

Director, IT Business Partner

Celgene

Dr. Ping Du is Director of IT Business Partner at Celgene responsible for IT business relationship management in support of drug discovery. Prior to Celgene, Dr. Du was Sr. Director, Research Informatics at Allergan, where he led research analytics, IT strategy, and delivery in drug discovery, non-clinical research, and pharmaceutical sciences. He was Director of Informatics at Lexicon Pharmaceuticals, Senior Scientist of Computational Chemistry at Synaptic Pharmaceutical Corporation, and Computational Chemist at Molecular Research Institute. Dr. Du received his PhD degree from the University of Washington, BS degree from Sichuan University, and completed Computer Science studies in New Jersey Institute of Technology.
 

John Eksterowicz

Associate Director

ORIC Pharmaceuticals

John Eksterowicz leads the computational chemistry, cheminformatics and structural biology efforts at ORIC, having joined in the fall of 2014 at the company’s inception. ORIC focuses on advancing new treatments towards cancers that have developed resistance to existing therapies. Prior to joining ORIC, John worked at Amgen, Celera Genomics and Combichem, and completed his postdoctoral training at UCSF after receiving his Ph.D. from UCLA.
 

Kevin Riehle

Lead Programmer / Analyst

Baylor College of Medicine

Kevin Riehle received a Bachelor of Science in Biology with an emphasis on molecular genetics, disease gene evolution, and bioinformatics in 2005 from the University of Dayton in Dayton, Ohio followed by a minor in Philosophy. Continuing his work with biology and computer science faculty, he initiated a pilot Master of Computer Science degree with an emphasis on bioinformatics and artificial intelligence. He has been at Baylor College of Medicine for over 7 years in the Bioinformatics Research Laboratory and has worked on many ‘omics’ projects ranging from metagenomics to cancer research to small molecule drug discovery.
 

Vickie Tsui

Senior Scientist

Genentech

Vickie Tsui is a Senior Scientist in the Computational Drug Discovery group within the Department of Discovery Chemistry at Genentech. She obtained her B.Sc. from Yale University where she was introduced to computational chemistry by Profession William Jorgensen. She then went on to earn her Ph.D. from the Scripps Research Institute, under the guidance of Professor David Case. Since joining Genentech in 2002, Vickie has applied computational modeling to a variety of targets, and has led therapeutic as well as software infrastructure projects.
 

John Apathy

VP R&D Informatics

Celgene

John Apathy joined Celgene in April, 2103 to lead the R&D Informatics efforts for Celgene’s IT organization. He has over 30 years of experience in R&D and IT across the Pharmaceutical/Biotech, Life Sciences and Management Consulting industries. John’s knowledge and expertise is based upon leadership positions within both the Pharmaceutical industry and Management Consulting at Celgene, GlaxoSmithKline, Pfizer, Wyeth, Accenture, Solutia Pharmaceutical Advisors, PA Consulting Group, and Eli Lilly & Company. A Biochemist by training, John has a M.Sc. in Biology/Immunology and an MBA in Strategy/Marketing. The focus of his career has been working with colleagues and clients at the boundary of science and business, delivering high-value results and capabilities for world-class Pharmaceutical, Biotech, and Life Sciences companies. John is an experienced leader in the strategies, processes, data, and systems for development and commercialization of new pharmaceutical products. His skills and experience includes the development and delivery of business and IT strategy, large-scale program management, product development processes, life-cycle extension, product launch, and big data analytics. Recently John has focused on the development of IT strategy for both the Research and Early Development and the Medical Development functions within Celgene, combining technical knowledge with business change leadership, problem-solving, technology strategy development, and enterprise information management. John has led the design and implementation of large enterprise solutions such as the Dotmatics platform for Discovery Research, the Medidata platform for clinical trial planning and management, as well as the IBM Watson for Patient Safety platform which leverages cognitive computing to increase efficiency and accuracy of Pharmacovigilance business capabilities.
 

Michael Beluch

Lead, Digital Capability Management, Leads Discovery and Optimization

Bristol-Myers Squibb

Mike Beluch is the Lead Digital Capability Manager for the Leads Discovery & Optimization group at Bristol-Myers Squibb. Mike has worked in the chemical and pharmaceutical industries for 25 years, starting his career at the bench as a Molecular Biologist, specializing for many years in nuclear hormone receptors and cholesterol efflux pathways. In 2004, Mike transitioned to IT at BMS, advancing a 'user-perspective', while working to develop, integrate, and support applications used in Research and Discovery Biology. His responsibilities have been to support existing and emerging technologies in the High-throughput screening group via software development and third-party software integration. In 2019, Mike transitioned to a broader role as a DCM Lead for LDO, responsible for defining strategic technology road-maps and developing solution architectures for new business capabilities.
 

John Faver

Cheminformatics Programmer

Baylor College

John Faver is a computational chemist focused on the intersection of data science and small-molecule drug discovery. He received a Ph.D. in Computational Chemistry from the University of Florida in 2012 while working with Prof. Kenneth M. Merz Jr. on methods for predicting modeling errors in biomolecular simulations. John then worked with Prof. William Jorgensen at Yale University to develop and apply computational methods for hit discovery and lead optimization. In 2015 he joined the Center for Drug Discovery at Baylor College of Medicine as an instructor and Cheminformatics leader.
 

William Janzen

Executive Director of Lead Discovery

Epizyme, Inc.

William P. Janzen is the Executive Director of Lead Discovery at Epizyme, Inc. Mr. Janzen has over twenty five years of experience in innovative drug discovery and has been a leader in high throughput screening and lead generation in academics, start-up companies and large pharmaceutical ventures. He has held executive and operational positions including Director of Assay Development and Compound Profiling at UNC, President and Chief Operating Officer of Amphora Discovery and Director of Lead Generation Technologies at Eli Lilly and Company.
 

John Keilty

Chief Data Sciences Officer

Third Rock Ventures

John currently serves as the Chief Data Sciences Officer at Decibel Therapeutics and as the General Manger of the TRV platform team. This group works to develop, implement and refine technology roadmaps for companies across the portfolio with a focus on the identification and integration of drug discovery and development technology platforms.

Prior to joining Third Rock, John was the vice president of information technology and informatics at Infinity Pharmaceuticals where he was responsible for information systems, software development, computational science, biostatistics, clinical data management and clinical informatics. Over the course of almost 13 years at Infinity, John had the unique opportunity to play a critical role in the genesis and evolution of the company's science, technology and business. Before joining Infinity in 2002, John was an early member of Millennium Pharmaceuticals where he held various roles of increasing responsibility, including senior manager of molecular research services with broad ownership for the creation, management, implementation and transfer of much of the company’s core genomic technologies. Before Millennium, John worked in the Howard Hughes lab of Michael Green at the University of Massachusetts Medical Center, focusing on basic research in transcription and gene splicing. John received his B.A. in biology from Clark University and his M.S. in bioinformatics from Brandeis University.
 

Steve May

Associate Director

Applied Technology

I’ve worked for Incyte Corporation for the past 13 years in the Applied Technology Group. My primary responsibilities at Incyte are to manage, support, and develop bioinformatics applications. Prior to Incyte I spend 3 years as an application developer and systems architect at PNC Bank, and 3 years at Rhône-Poulenc Rorer Pharmaceuticals as a clinical trial data manager and application scientist. I graduated from Millersville University with a BSc in Biology and a minor in Chemistry and have competed several certifications in application design and development.
 

Christopher Roberts

Entrepreneur in Residence

SR-One Ltd.

Dr. Roberts joined SR-One, the corporate venture capital arm of GlaxoSmithKline, in 2017 as an Entrepreneur in Residence. Before coming to SR-One, Chris was the VP of Chemistry and Early Development at Syros Pharmaceuticals, a Cambridge, MA based biotech focused on gene control and drugging transcription, where he built and led a variety of discovery and development functions and delivered two assets into clinical development in oncology. Prior to joining Syros in 2015, he was with GSK in North Carolina where he was most recently the VP, Antiviral (Host Defense) Discovery Performance Unit (DPU) and where he also led multiple clinical development projects. He joined GSK as Senior Director of HCV Medicinal Chemistry via acquisition of Redwood City, CA based Genelabs Technologies. Joining Genelabs in the late 90’s as a medicinal chemist, he was significantly involved in establishing the Genelabs’ HCV research focus and ultimately building the pipeline that led to collaborations with Gilead and Novartis, and finally the acquisition by GSK. He completed a post-doctoral fellowship at the University of Bern, Switzerland and attained his Ph.D. in organic chemistry from University of California, Riverside. A native of the US west coast, he grew up in Northern California and received his bachelors degree in chemistry from Whitworth University (where he also played college basketball).
 

Michael Bower

Senior Research Scientist

Vertex Pharmaceuticals

Michael achieved his BS in chemistry at the university of Delaware, and a PhD in pharmaceutical chemistry at UC San Francisco, working in Fred Cohen’s lab, where he mostly wrote code for building homology models.

He then worked for SmithKline Beecham, that became GlaxoSmithKline. He then became the director of computational chemistry with Incyte in Delaware and was there for 10 years. And for the last 5 years he's worked at Vertex Pharmaceuticals, mostly in project support.
 

Andreas Gumm

Head of Chemical Group Research Excellence

Clariant

Todd Herbst

DMPK Program Manager

CHDI Foundation

Todd has over 20 years of experience in drug discovery and development in multiple CNS therapeutic indications. Todd’s areas of expertise cover pharmacokinetics, toxicology, behavior, drug formulation, and bioanalytics. He started his career as a Research Associate running a discovery lab focused on onset juvenal diabetes mellitus at Children’s Hospital of Orange County. Todd then moved to Cortex Pharmaceuticals in Irvine and during his tenure there helped develop and advance the Ampakine® platform in the areas of; cognition, neurological disorders, stroke, and respiratory depression. Todd is currently at CHDI as the Pharmacokinetics Program Manager joining the effort to develop therapeutics for Huntington’s Disease in 2010. Todd received his BS in Biological Sciences from the University of California-Irvine, specializing in neuroanatomy and biochemistry.
 

Joseph Kennedy

Associate Director of IT & Informatics

Tango Therapeutics

Joseph is currently the Associate Director of IT & Informatics at Tango Therapeutics, Inc. At Tango, Joseph is responsible for the development and implementation of IT and informatics strategies across the company’s functional areas. Prior to this role, Joseph was the Manager of Research Informatics Applications at Sage Therapeutics, Inc. where he owned the planning, implementation and maintenance of all informatics systems across the research portfolio. Before joining Sage, Joseph spent several years at Vertex Pharmaceuticals, Inc. first as a medicinal chemist and then as an applications analyst in the Research Computing group. He has experience building home-grown research applications as well as designing and executing the integration of commercially available systems. Joseph received his B.S. in chemistry from Boston College and his M.S. in Organic Chemistry from Yale University.
 

Request a demonstration or
ask us a question